{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:37:02Z","timestamp":1793371022298,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jaad.2026.09.023","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:47:03Z","timestamp":1789602423000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Short-term prognostic factors of rituximab combined with glucocorticoids in the treatment of pemphigus: A multicenter retrospective study"],"prefix":"10.1016","author":[{"given":"Zhili","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiefeng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuomin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqian","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiu","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7917-7356","authenticated-orcid":false,"given":"Ruzeng","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10201","key":"10.1016\/j.jaad.2026.09.023_bib1","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0140-6736(19)31778-7","article-title":"Pemphigus","volume":"394","author":"Schmidt","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jaad.2026.09.023_bib2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1001\/archderm.1996.03890260105016","article-title":"The adjuvant therapy of pemphigus. An update","volume":"132","author":"Bystryn","year":"1996","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2026.09.023_bib3","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/bjd.14463","article-title":"Comorbidities and inpatient mortality for pemphigus in the U.S.A","volume":"174","author":"Hsu","year":"2016","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2026.09.023_bib4","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jaad.2017.04.1116","article-title":"Cumulative oral corticosteroid use increases risk of glucocorticoid-related adverse events in patients with newly diagnosed pemphigus","volume":"77","author":"Wormser","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2026.09.023_bib5","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jaad.2017.01.059","article-title":"Venous thromboembolism in patients with pemphigus: a cohort study","volume":"77","author":"Leshem","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2026.09.023_bib6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4103\/idoj.idoj_397_21","article-title":"The demographic attributes, clinical features, and optimal management of 143 patients with pemphigus: a retrospective observational study from a tertiary care center of India","volume":"13","author":"Mahajan","year":"2022","journal-title":"Indian Dermatol Online J"},{"issue":"2","key":"10.1016\/j.jaad.2026.09.023_bib7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00128071-200708020-00004","article-title":"Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris","volume":"8","author":"Olszewska","year":"2007","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2026.09.023_bib8","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.jaad.2006.07.019","article-title":"Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2)","volume":"56","author":"Graves","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2026.09.023_bib9","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/jdv.16752","article-title":"Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)","volume":"34","author":"Joly","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10083","key":"10.1016\/j.jaad.2026.09.023_bib10","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jaad.2026.09.023_bib11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2133.2011.10663.x","article-title":"Low-dose rituximab is effective in pemphigus","volume":"166","author":"Horv\u00e1th","year":"2012","journal-title":"Br J Dermatol"},{"issue":"17","key":"10.1016\/j.jaad.2026.09.023_bib12","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1056\/NEJMoa062930","article-title":"Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin","volume":"355","author":"Ahmed","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2026.09.023_bib13","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.intimp.2017.11.005","article-title":"Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: a systematic review","volume":"54","author":"Tavakolpour","year":"2018","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"10.1016\/j.jaad.2026.09.023_bib14","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1365-4632.2012.5847.x","article-title":"Adjuvant rituximab in the treatment of pemphigus vulgaris: a phase II clinical trial","volume":"52","author":"Balighi","year":"2013","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2026.09.023_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12763","article-title":"Rituximab therapy in pemphigus: a long-term follow-up","volume":"32","author":"Loi","year":"2019","journal-title":"Dermatol Ther"},{"issue":"8","key":"10.1016\/j.jaad.2026.09.023_bib16","doi-asserted-by":"crossref","first-page":"928","DOI":"10.2340\/00015555-2116","article-title":"Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens","volume":"95","author":"Wang","year":"2015","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2026.09.023_bib17","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jaad.2018.02.021","article-title":"Diagnosis and management of pemphigus: recommendations of an international panel of experts","volume":"82","author":"Murrell","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2026.09.023_bib18","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jaad.2025.05.1374","article-title":"Efficacy, safety, and B-cell depletion capacity of 3 rituximab dosing regimens in the treatment of moderate-to-severe pemphigus vulgaris and pemphigus foliaceus: a 52-week clinical trial","volume":"93","author":"Cao","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2026.09.023_bib19","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2024.2302071","article-title":"The efficacy and safety of low-dose rituximab in the treatment of pemphigus vulgaris: a cohort study","volume":"35","author":"Zhou","year":"2024","journal-title":"J Dermatol Treat"},{"issue":"2","key":"10.1016\/j.jaad.2026.09.023_bib20","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaad.2022.06.1187","article-title":"Clinical observation of different doses of rituximab for the treatment of severe pemphigus: a single-center prospective cohort study","volume":"88","author":"Zhang","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2026.09.023_bib21","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamadermatol.2024.6130","article-title":"Optimizing pemphigus management with rituximab and short-term relapse predictors","volume":"161","author":"H\u00e9bert","year":"2025","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2026.09.023_bib22","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jaad.2017.07.012","article-title":"Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab","volume":"77","author":"Albers","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2026.09.023_bib23","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar3908","article-title":"B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies","volume":"15 Suppl 1","author":"Leandro","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.jaad.2026.09.023_bib24","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s00403-025-03827-6","article-title":"Impact of rituximab on IgG and IgM levels in patients with autoimmune bullous diseases: a cohort study","volume":"317","author":"Dalvand","year":"2025","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"10.1016\/j.jaad.2026.09.023_bib25","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2133.2011.10658.x","article-title":"Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy","volume":"166","author":"Feldman","year":"2012","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2026.09.023_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102466","article-title":"Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia","volume":"19","author":"Kridin","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.jaad.2026.09.023_bib27","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/acr.22993","article-title":"Pragmatic treatment of patients with systemic lupus erythematosus with rituximab: long-term effects on serum immunoglobulins","volume":"69","author":"Reddy","year":"2017","journal-title":"Arthritis Care Res"},{"issue":"4","key":"10.1016\/j.jaad.2026.09.023_bib28","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.clindermatol.2013.01.004","article-title":"Pemphigus: etiology, pathogenesis, and inducing or triggering factors: facts and controversies","volume":"31","author":"Ruocco","year":"2013","journal-title":"Clin Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2026.09.023_bib29","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/bjd.12961","article-title":"Herpes simplex virus reactivation as a trigger of mucous lesions in pemphigus vulgaris","volume":"171","author":"Kurata","year":"2014","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2026.09.023_bib30","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1111\/bjd.15658","article-title":"Identification of factors associated with treatment refractoriness of oral lesions in pemphigus vulgaris","volume":"177","author":"Kumar","year":"2017","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2026.09.023_bib31","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.14955","article-title":"Comparison of rituximab and intravenous immunoglobulin in the treatment of autoimmune bullous diseases: real-life data from a single centre","volume":"75","author":"Huseynova Terzi","year":"2021","journal-title":"Int J Clin Pract"},{"issue":"12","key":"10.1016\/j.jaad.2026.09.023_bib32","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1001\/jamadermatol.2019.3236","article-title":"Factors associated with complete remission after rituximab therapy for pemphigus","volume":"155","author":"Kushner","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2026.09.023_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.8208","article-title":"Combination therapy for management of pemphigus patients with unexpected therapeutic response to rituximab: a report of five cases","volume":"11","author":"Aryanian","year":"2023","journal-title":"Clin Case Rep"},{"issue":"8","key":"10.1016\/j.jaad.2026.09.023_bib34","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1111\/bcp.13271","article-title":"Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome","volume":"83","author":"Rozman","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.jaad.2026.09.023_bib35","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3390\/cimb47050357","article-title":"The mechanisms of chronic inflammation in obesity and potential therapeutic strategies: a narrative review","volume":"47","author":"Gkrinia","year":"2025","journal-title":"Curr Issues Mol Biol"},{"issue":"2","key":"10.1016\/j.jaad.2026.09.023_bib36","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s12026-018-8989-4","article-title":"Impaired natural killer cell subset phenotypes in human obesity","volume":"66","author":"B\u00e4hr","year":"2018","journal-title":"Immunol Res"},{"issue":"4","key":"10.1016\/j.jaad.2026.09.023_bib37","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jaad.2025.12.030","article-title":"Characterization and treatment outcomes of rituximab therapy in super-responders and rituximab-refractory pemphigus patients: a single-center retrospective study","volume":"94","author":"Wu","year":"2026","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2026.09.023_bib38","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.jaad.2020.12.062","article-title":"A 10-year retrospective cohort analysis of rituximab for the treatment of pemphigus in a Chinese population","volume":"85","author":"Chang","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2026.09.023_bib39","article-title":"Efficacy and safety of low dose rituximab in pemphigus: an updated systematic review and meta-analysis","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226035231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226035231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:27:55Z","timestamp":1793370475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962226035231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":39,"alternative-id":["S0190962226035231"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2026.09.023","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Short-term prognostic factors of rituximab combined with glucocorticoids in the treatment of pemphigus: A multicenter retrospective study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2026.09.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}